vip receptor

[D-p-Cl-Phe6,Leu17]-VIP acetate is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor (IC50 = 125.8 nM).

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors.

[K15,R16,L27]VIP(1-7) GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7) GRF(8-27), acting as a selective agonist for the VIP 1 receptor with IC50 values of 2 nM for human VIP 1, 1 nM for rat VIP 1, and 30,000 nM for rat VIP 2 receptors. The peptide's acronym, VIP, stands for Vasoactive Intestinal Polypeptide.

PHM-27 (human) acetate is the endogenous peptide product of prepro-VIP (human), an agonist of the calcitonin receptor (EC 50 = 11 nM). Transgenic mice overexpressing PHM-27 (human) acetate in pancreatic β-islets exhibited enhanced glucose-induced insulin secretion.

Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr (free acid) acts as a selective and potent antagonist of the VPAC2 receptor [1].

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist utilized for research in various cancers, including non-small cell lung cancer (NSCLC) [1].

Peptide T, an octapeptide from the V2 region of HIV-1 gp120, is a synthetic octapeptide that potentially acts through competitive inhibition of gp120 binding to the CD4 receptor, as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.

[D-p-Cl-Phe6,Leu17]-VIP TFA acts as a competitive and selective antagonist of the vasoactive intestinal peptide (VIP) receptor, with an IC50 of 125.8 nM, and shows no activity on glucagon, secretin, or growth hormone-releasing factor (GRF) receptors [1] [2] [3].

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist for the vasoactive intestinal peptide 1 (VIP 1) receptor.

PACAP (6-27) (human, ovine, rat) is an antagonist for the PACAP receptor, inhibiting the catecholamine response of the canine adrenal gland to vasoactive intestinal peptide (VIP), making it a valuable compound for research into cardiovascular and neurological disorders [1].

Endogenous peptide product of human prepro-VIP and analog of porcine PHI-27; potent agonist for the human calcitonin receptor (EC50 = 11 nM). Transgenic mice expressing the human VIP/PHM 27 gene in pancreatic β-islets display enhanced glucose-induced insu

[K15,R16,L27]VIP(1-7) GRF(8-27), a selective agonist for the VIP 1 receptor, demonstrates binding IC50 values of 2 nM for the human VIP 1, 1 nM for the rat VIP 1, and 30,000 nM for the rat VIP 2 receptors, respectively [1]. VIP stands for VASOACTIVE Intestinal Polypeptide.